Balfaxar Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to widespread use of vitamin k antagonists, need for urgent bleeding control, hospital adoption of pcc therapy, growth in invasive procedures, established emergency protocols.

The growth in the forecast period can be attributed to increase in elderly patient surgeries, rising anticoagulant usage, expansion of trauma centers, improved awareness of rapid reversal therapies, favorable clinical guidelines. Major trends in the forecast period include rising use of pccs for anticoagulant reversal, increased demand in emergency surgical settings, preference for rapid acting coagulation products, growth in aging surgical population, expansion of hospital based emergency care.

The increasing prevalence of blood disorders is expected to drive the growth of the balfaxar market in the coming years. Blood disorders are conditions that impact components of the blood, including red blood cells, white blood cells, platelets, or plasma. The rise in blood disorders is largely linked to the growing incidence of chronic diseases, which affect blood health and require continuous monitoring. Balfaxar helps manage blood disorders by providing rapid and effective reversal of anticoagulation, making it essential for patients experiencing major bleeding or requiring urgent surgery. It improves clinical outcomes by delivering concentrated clotting factors that quickly restore hemostasis, enhancing treatment efficiency and patient safety. For example, in July 2025, the National Blood Authority, an Australia-based blood management agency, reported 2,788 patients living with hereditary haemophilia A (HMA) in 2023-2024, up from 2,681 patients in 2022-2023. Thus, the rising incidence of blood disorders is supporting the growth of the balfaxar market.

The rising number of surgical procedures is expected to support the growth of the balfaxar market in the coming years. Surgical procedures involve manual or instrumental techniques to diagnose, treat, or repair conditions within the body. Growth in surgeries is driven by advances in medical technology, broader healthcare access, and increasing demand for cosmetic and corrective treatments. Balfaxar rapidly reverses the effects of vitamin K antagonists (VKAs), restoring normal blood clotting and preventing excessive bleeding during surgery. This ensures proper hemostasis, reduces the risk of complications, and promotes safer surgical outcomes by quickly replenishing essential clotting factors. For example, in June 2024, the American Society of Plastic Surgeons (ASPS), a U.S.-based medical organization, reported that liposuction remained the most in-demand plastic surgery procedure in 2023, with nearly 350,000 procedures performed, marking a 7% increase compared to 2022. Therefore, the growing number of surgical procedures is driving the growth of the balfaxar market.

Major companies in the balfaxar market are focusing on developing advanced therapeutic solutions, such as prothrombin complex concentrate (PCC), to improve patient outcomes in bleeding disorder management. PCC is a blood-derived product containing clotting factors II, VII, IX, and X, used to rapidly reverse coagulation deficiencies in patients with vitamin K deficiency or those on anticoagulant therapy. For example, in July 2023, Octapharma USA Inc., a U.S.-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Balfaxar, a non-activated, four-factor prothrombin complex concentrate (4F-PCC) designed for urgent reversal of acquired coagulation factor deficiency due to vitamin K antagonist (VKA) therapy, such as warfarin. It contains vitamin K-dependent clotting factors (II, VII, IX, and X) along with antithrombotic proteins C and S. Balfaxar is supplied as a lyophilized powder for reconstitution, accompanied by sterile water for injection and the Nextaro transfer device, enhancing safety and ease of administration.

Major companies operating in the balfaxar market are Octapharma AG.

North America was the largest region in the balfaxar market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the balfaxar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the balfaxar market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the balfaxar market by increasing costs associated with plasma fractionation inputs, manufacturing equipment, and sterile delivery systems. These effects are more pronounced in regions dependent on imported plasma derivatives such as asia pacific. Hospital acquisition costs have risen in emergency care settings. However, tariffs have driven investment in regional plasma processing. This improves long term supply resilience for coagulation products.

The balfaxar market research report is one of a series of new reports that provides balfaxar market statistics, including balfaxar industry global market size, regional shares, competitors with a balfaxar market share, detailed balfaxar market segments, market trends and opportunities, and any further data you may need to thrive in the balfaxar industry. This balfaxar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Balfaxar is a non-activated prothrombin complex concentrate (4F-PCC) developed to quickly reverse the effects of vitamin K antagonists in adult patients undergoing surgery or invasive procedures. By replenishing missing clotting factors, Balfaxar restores normal blood coagulation and helps reduce the risk of bleeding.

The primary Balfaxar formulations include 4-factor and 3-factor prothrombin complex concentrates. The 4-factor prothrombin complex concentrate contains factors II, VII, IX, and X to reestablish clotting factor balance and manage bleeding in patients with bleeding disorders or during surgical procedures. It has multiple clinical uses, such as urgent reversal of VKA therapy and coagulation factor replacement, and is distributed through various channels, including hospitals, ambulatory surgery centers, specialty clinics, and others. The medication is utilized by a range of end users, including adult and geriatric patients.

The balfaxar market consists of sales of balfaxar syringes and balfaxar infusion sets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.